| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Research Overview
This Frost & Sullivan research service titled Clinical Management of Obesity
provides an in-depth analysis about the various commercial weight-loss
products and therapies currently available in the market, and those on the
verge of commercialization. In this research service, Frost & Sullivan's
expert analysts thoroughly examine the following applications/technologies:
diet therapies, lifestyle modifications, pharmacotherapy, bariatric surgeries,
and medical devices for weight loss.
This analysis is available through our Technical Insights - Healthcare Growth
Partnership Services program. With this program, clients receive
industry-leading market research such as this, along with technical and
econometric data and many interactive features including Analyst Inquiry Time
and Client Councils.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) program that
provides established and emerging firms with powerful growth visions. Moving
beyond token mission statements, GPS provides an actionable vision to growth
consulting partners by illustrating how key intelligence and strategic
research based on defined goals can guide day-to-day behavior and overall
company direction. The foundation of Frost & Sullivan's GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximize the potential for growth within a firm's internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programs that deliver improved market success. Frost & Sullivan's
strengths lie in combining strategic understanding with market expertise and
applying these with absolute commitment to its clients' growth.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
- Scope and Methodology
- Scope and Segmentation
- Methodology
- Key Findings
- An Overview of the Weightloss Industry
- Noteworthy Technology Developments--Companies
- Noteworthy Technology Developments--Universities
2 CLINICAL MANAGEMENT OF OBESITY--TECHNOLOGY ANALYSIS
- Obesity--Overview
- Definitions
- Causes and Associated Health Problems
- Technology Primer
- Diet Therapy and Lifestyle Changes
- Pharmacotherapy
- Bariatric Surgery
- Medical Devices
- Technology Impact Analysis and Future Trends
3 TECHNOLOGY ADOPTION FACTOR ANALYSIS
- Pharmacotherapy
- Technology Accelerators
- Technology Roadblocks
- Medical Devices
- Technology Accelerators
- Technology Roadblocks
- Bariatric Surgeries
- Technology Accelerators
- Technology Roadblocks
- Funding Analysis; Collaborations and Mergers
- Companies
- Universities and Government Institutions
- Collaborations and Mergers
4 ADVANCEMENTS IN CLINICAL MANAGEMENT OF OBESITY
- Technology Innovations in Companies--North America
- A Novel Antiobesity Drug Suppresses Appetite through Inhibition of
Serotonin Reuptake--USA
- A Novel Appetite Suppressant Selectively Inhibits Cannabinoid
Receptors--USA
- A Novel Small Molecule for the Treatment of Obesity--USA
- A Natural Peptide Hormone Suppresses Appetite and Enhances Metabolic
Rate--USA
- Ghrelin Receptor Modulators Offer Potential Obesity Treatment
Options--Canada
- Neurostimulation Technique to Treat Chronic Obesity--USA
- A Novel Small Molecule Drug to Treat Obesity--USA
- A Unique and Selective Hydroxy Tryptamine Receptor Agonist to Treat
Obesity--USA
- A Novel and Selective Hydroxy Tryptamine Receptor Agonist for Obesity
Treatment--USA
- A Novel Technology Leads to Apoptosis of Fat Cells--USA
- Adjustable and Reversible Gastric Banding Technique to Treat Morbid
Obesity--USA
- Technology Innovations in Companies--Europe
- Antiobesity Drug Works by Blocking Fat Absorption--UK
- Potent and Selective Cannabinoid Receptor Antagonists as Novel
Antiobesity Agents--UK
- A Novel Single Peptide Drug with a Dual Receptor Agonist Action to Treat
Obesity--Denmark
- A Novel Antiobesity Drug Targets Thyroid Hormone Receptors--Sweden
- A Natural Appetite Suppressant from Korean Pine Nuts--Netherlands
- A Unique Gastro Intestinal Lipase Inhibitor Aids Weight Loss--UK
- A Novel Vaccine Treats Obesity by Induction of Ghrelin Specific
Antibodies--Switzerland
- Technology Innovations in Companies--APAC
- A Novel Peptide-Based Drug to Treat Obesity--Australia
- Potential Obesity Therapies through the Prevention of
Adipogenesis--Australia
- A Pan Peroxisome Proliferator-Activated Receptor Agonist Burns Fat--India
- Cannabinoid Receptor Antagonist Drug Therapy for Obesity and Related
Disorders--India
- A Potential Antiobesity Drug Inhibits Alpha-Amylase--India
- Technology Innovations in Universities--World
- Hormone Discovery Offers Hope for Obesity Drug--USA
- Stomach Hormone Controls Appetite--UK
- Study Finds Effect of Dietary Calcium on Weightloss--Denmark
- Research Finds Relationship between Metabolism and Appetite
Suppression--Australia
- Study Shows the Effect of Second Messenger Molecule on Satiety--UK
5 PATENTS AND KEY CONTACTS
- Patents
- US Patents--2006
- US Patents--2004 to 2005
- Key Contacts
- Company Contacts
- University Contacts
6 FROST AND SULLIVAN 2006 SCIENCE AND TECHNOLOGY AWARDS
- Excellence in Technology Award
- Award Description
- Award Recipient
- Product Innovation Award
- Award Description
- Award Recipient
- Excellence in Research Award
- Award Description
- Award Recipient
7 DECISION SUPPORT DATABASE
- Healthcare and Pharmaceutical Expenditure--World
- Total Healthcare Expenditure--World (1996 to 2006)
- Government Healthcare Expenditure--World (1996 to 2006)
- Private Healthcare Expenditure--World (1996 to 2006)
- Pharmaceutical R&D Expenditure--World (1996 to 2006)
- Healthcare Infrastructure--World
- No. of Hospitals--World (1996 to 2006)
- No. of Physicians--World (1996 to 2006)
- No. of Pharmacists--World (1996 to 2006)
- Pervalence of Obesity-Related Health Risks--World
- Prevalence of Diabetes--World (1996 to 2006)
- Prevalence of Hypertension--World (1996 to 2006)
- Incidence of Stroke--World (1996 to 2006)
- Prevalence of Coronary Heart Disease--World (1996 to 2006)
|
